Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oragenics Inc OGEN

Healthcare Biotechnology
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It is focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for... see more

Recent & Breaking News (NYSEAM:OGEN)

Oragenics Appoints Key Hires to Drive Lantibiotic Platform Growth and Expansion

Business Wire September 10, 2014

Oragenics Advances Towards Identification of Lead Antibiotic Clinical Candidate

Business Wire May 6, 2014

Oragenics Appoints Al Fosmoe as Senior Vice President of Operations/Product Development

Business Wire April 22, 2014

30+ Leading Small-Cap Companies to Present at RedChip Global Online CEO Conference, April 23-24

GlobeNewswire April 21, 2014

Oragenics to Present at Biotech Showcase 2014

Business Wire January 14, 2014

Oragenics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity

Business Wire January 13, 2014

RedChip TV Debuts on Bloomberg Asia

Globe Newswire January 2, 2014

Oragenics Announces Completion of Public Offering of Common Stock

Business Wire November 20, 2013

Oragenics Prices Public Offering of Common Stock

Business Wire November 15, 2013

Oragenics Announces Proposed Public Offering of Common Stock

Business Wire November 14, 2013

Oragenics Announces Breakthrough Antibiotic Analog Generation in Intrexon Collaboration

Business Wire October 31, 2013

Oragenics and Intrexon to Develop Genetically Modified Probiotics

PR Newswire October 1, 2013

Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project

Business Wire August 26, 2013

Oragenics to Join the Russell Microcap® Index

Business Wire June 25, 2013

Oragenics Launches New Professional and Consumer Commercial Websites

Business Wire May 2, 2013

Oragenics To Present Oral Care Probiotics Seminar at SupplySide MarketPlace 2013

Business Wire April 30, 2013

Oragenics Announces Approval of Common Stock Listing on NYSE MKT

Business Wire April 8, 2013

Oragenics Receives First European Patent for ProBiora3® Probiotic Blend

Business Wire March 12, 2013

Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140

Business Wire February 12, 2013

Oragenics Receives European Union CPNP Notifications for ProBiora3® Cosmetic Tablets

Business Wire February 11, 2013